Acceleron Pharma Inc. (NASDAQ:XLRN) saw some unusual options trading on Friday. Stock investors bought 2,255 call options on the stock. This is an increase of 832% compared to the average volume of 242 call options.
Acceleron Pharma stock traded down $1.98 during trading on Friday, reaching $122.05. 236,090 shares of the company were exchanged, compared to its average volume of 370,493. The stock’s 50 day simple moving average is $133.79 and its two-hundred day simple moving average is $123.57. The company has a market capitalization of $7.39 billion, a P/E ratio of -47.89 and a beta of 0.59. Acceleron Pharma has a 52-week low of $85.32 and a 52-week high of $146.15.
Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Thursday, February 25th. The biopharmaceutical company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.66) by ($0.29). The firm had revenue of $25.87 million for the quarter, compared to analysts’ expectations of $25.68 million. Acceleron Pharma had a negative net margin of 157.84% and a negative return on equity of 31.62%. Equities research analysts predict that Acceleron Pharma will post -2.47 earnings per share for the current year.
Several analysts have commented on the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $132.00 price objective on shares of Acceleron Pharma in a report on Monday, March 29th. Raymond James raised their target price on Acceleron Pharma from $155.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Tuesday, January 19th. JPMorgan Chase & Co. raised their target price on Acceleron Pharma from $133.00 to $153.00 and gave the company an “overweight” rating in a research report on Friday, January 29th. Citigroup raised their target price on Acceleron Pharma from $137.00 to $171.00 and gave the company a “buy” rating in a research report on Monday, March 8th. Finally, SVB Leerink restated a “market perform” rating and issued a $148.00 target price on shares of Acceleron Pharma in a research report on Monday, March 29th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $146.80.
Expert Jeff Clark is releasing his #1 stock to trade in 2021.
Since he started recommending this stock, you could have used it for gains as high as 269% and even 273%… in as little as 8 days.
In other Acceleron Pharma news, Director Joseph S. Zakrzewski sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 5th. The stock was sold at an average price of $140.73, for a total value of $1,407,300.00. Following the sale, the director now directly owns 44,499 shares of the company’s stock, valued at $6,262,344.27. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 2.50% of the stock is currently owned by company insiders.
Large investors have recently modified their holdings of the stock. State of Alaska Department of Revenue grew its stake in Acceleron Pharma by 20.3% in the 1st quarter. State of Alaska Department of Revenue now owns 576 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 97 shares in the last quarter. Xponance Inc. grew its stake in Acceleron Pharma by 2.5% in the 4th quarter. Xponance Inc. now owns 5,089 shares of the biopharmaceutical company’s stock worth $651,000 after buying an additional 124 shares in the last quarter. LPL Financial LLC grew its stake in Acceleron Pharma by 7.2% in the 4th quarter. LPL Financial LLC now owns 2,325 shares of the biopharmaceutical company’s stock worth $297,000 after buying an additional 157 shares in the last quarter. IFP Advisors Inc grew its stake in Acceleron Pharma by 15.0% in the 4th quarter. IFP Advisors Inc now owns 1,222 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 159 shares in the last quarter. Finally, Sei Investments Co. grew its stake in Acceleron Pharma by 0.3% in the 3rd quarter. Sei Investments Co. now owns 51,712 shares of the biopharmaceutical company’s stock worth $5,819,000 after buying an additional 166 shares in the last quarter. 79.78% of the stock is owned by institutional investors.
About Acceleron Pharma
Acceleron Pharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. It offers REBLOZYL (luspatercept-aamt), a first-in-class erythroid maturation agent, for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia.
See Also: How Do Mutual Funds Work?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Why do analysts give a neutral rating?
Should you or shouldn’t you? Many investors are wondering if it’s time to take some profit. With so much uncertainty in the market, there can be a temptation to take your profits and run. That may or may not be a good strategy. It’s true there are some speculative stocks that are going up on nothing but faith, trust, and pixie dust. But there are other stocks that may still be good buys despite continuing to grow.
Since the sell-off caused by the novel coronavirus and subsequent locking down of large portions of the economy, the stock market has recovered nearly all of its losses. The Federal Reserve has done its part by pledging to keep interest rates low for as long as it takes. New housing starts are up. Unemployment is coming down. There seems to be a lot of fuel for market bulls.
Still, if you’ve been holding one of the stocks in this presentation, it may be time for you to take some of the profits you’ve made. Many of the stocks in this presentation are being downgraded by analysts. And that means that there is likely to be downward pressure on the stock price.